Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

9 Meters Biopharma, Inc. - Common Stock (NQ:NMTR)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 9 Meters Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
Via ACCESSWIRE
News headline image
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
Via ACCESSWIRE
News headline image
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
Via ACCESSWIRE
News headline image
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
Via ACCESSWIRE
News headline image
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
Via ACCESSWIRE
News headline image
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
Via ACCESSWIRE
News headline image
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
Via ACCESSWIRE
News headline image
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy
Via ACCESSWIRE
News headline image
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
Via ACCESSWIRE
News headline image
9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meeting
Via ACCESSWIRE
News headline image
9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Via ACCESSWIRE
News headline image
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split
Via ACCESSWIRE
News headline image
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome
Via ACCESSWIRE
News headline image
9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
News headline image
9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress
Via ACCESSWIRE
News headline image
9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference
Via ACCESSWIRE
News headline image
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
Via ACCESSWIRE
News headline image
9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
RALEIGH, NC / ACCESSWIRE / June 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma to Participate in the 2022 BIO International Convention
RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis
RALEIGH, NC / ACCESSWIRE / May 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
- On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in June - Cash balance as of March 31, 2022, of $37.2 million is expected to... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease
RALEIGH, NC and SANTA ROSA, CA / ACCESSWIRE / April 20, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions
RALEIGH, NC / ACCESSWIRE / April 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.